Immutep Limited (PRRUF)
USD 0.2
(-26.74%)
USD 0.2
(-26.74%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 12.05 Million AUD | 9.82% |
| 2023 | 10.97 Million AUD | 35.68% |
| 2022 | 8.09 Million AUD | -7.61% |
| 2021 | 8.75 Million AUD | -34.13% |
| 2020 | 13.29 Million AUD | -17.68% |
| 2019 | 16.15 Million AUD | 19.86% |
| 2018 | 13.47 Million AUD | 59.84% |
| 2017 | 8.43 Million AUD | 16.51% |
| 2016 | 7.23 Million AUD | 14.98% |
| 2015 | 6.29 Million AUD | 125.93% |
| 2014 | 2.78 Million AUD | -21.88% |
| 2013 | 3.56 Million AUD | -19.95% |
| 2012 | 4.45 Million AUD | 75.28% |
| 2011 | 2.54 Million AUD | 14.29% |
| 2010 | 2.22 Million AUD | 228.41% |
| 2009 | 677.09 Thousand AUD | 260.51% |
| 2008 | 187.81 Thousand AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 FY | 12.05 Million AUD | 9.82% |
| 2024 Q2 | 8.14 Million AUD | 0.0% |
| 2024 Q4 | 12.05 Million AUD | 0.0% |
| 2023 Q2 | 9.32 Million AUD | 0.0% |
| 2023 Q4 | 10.97 Million AUD | 0.0% |
| 2023 FY | 10.97 Million AUD | 35.68% |
| 2022 FY | 8.09 Million AUD | -7.61% |
| 2022 Q4 | 8.09 Million AUD | 0.0% |
| 2022 Q2 | 11.32 Million AUD | 0.0% |
| 2021 Q2 | 15.78 Million AUD | 0.0% |
| 2021 FY | 8.75 Million AUD | -34.13% |
| 2021 Q4 | 8.75 Million AUD | 0.0% |
| 2020 Q4 | 13.29 Million AUD | 0.0% |
| 2020 FY | 13.29 Million AUD | -17.68% |
| 2020 Q2 | 14.92 Million AUD | 0.0% |
| 2019 FY | 16.15 Million AUD | 19.86% |
| 2019 Q4 | 16.15 Million AUD | 0.0% |
| 2019 Q2 | 14.7 Million AUD | 0.0% |
| 2018 Q4 | 13.47 Million AUD | 0.0% |
| 2018 Q2 | 9.91 Million AUD | 0.0% |
| 2018 FY | 13.47 Million AUD | 59.84% |
| 2017 Q4 | 8.43 Million AUD | 22.24% |
| 2017 Q3 | 6.89 Million AUD | -0.11% |
| 2017 Q2 | 6.9 Million AUD | 0.0% |
| 2017 FY | 8.43 Million AUD | 16.51% |
| 2016 Q2 | 7.72 Million AUD | 0.0% |
| 2016 FY | 7.23 Million AUD | 14.98% |
| 2016 Q4 | 7.23 Million AUD | 0.0% |
| 2015 FY | 6.29 Million AUD | 125.93% |
| 2015 Q4 | 6.29 Million AUD | 0.0% |
| 2015 Q2 | 16.33 Million AUD | 0.0% |
| 2014 FY | 2.78 Million AUD | -21.88% |
| 2014 Q4 | 2.78 Million AUD | 0.0% |
| 2014 Q2 | 2.8 Million AUD | 0.0% |
| 2013 Q4 | 3.56 Million AUD | 0.0% |
| 2013 FY | 3.56 Million AUD | -19.95% |
| 2013 Q2 | 2.98 Million AUD | 0.0% |
| 2012 FY | 4.45 Million AUD | 75.28% |
| 2012 Q4 | 4.45 Million AUD | 0.0% |
| 2011 FY | 2.54 Million AUD | 14.29% |
| 2010 FY | 2.22 Million AUD | 228.41% |
| 2009 FY | 677.09 Thousand AUD | 260.51% |
| 2008 FY | 187.81 Thousand AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1337.591% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -379.172% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -134.307% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 83.362% |
| GB Sciences, Inc. | 5.41 Million USD | -122.564% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -228.977% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -669.772% |
| Skye Bioscience, Inc. | 14.07 Million USD | 14.317% |
| Zenith Capital Corp. | 27.56 Thousand USD | -43635.859% |
| Agentix Corp. | 2.51 Million USD | -380.274% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -27.378% |
| Biomind Labs Inc. | 1.49 Million USD | -704.58% |
| ContraFect Corporation | 32.53 Million USD | 62.935% |
| CSL Limited | 18.62 Billion USD | 99.935% |
| CytoDyn Inc. | 127.89 Million USD | 90.572% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -740.914% |
| Neon Bloom, Inc. | 1.22 Million USD | -883.315% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 83.906% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -26876.774% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -213.067% |
| Regen BioPharma, Inc. | 5.45 Million USD | -120.931% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 79.568% |
| SQZ Biotechnologies Company | 50.03 Million USD | 75.904% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -499.839% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 77.38% |
| Intellipharmaceutics International Inc. | 12 Million USD | -0.406% |
| Mesoblast Limited | 188.44 Million USD | 93.602% |
| Marizyme, Inc. | 26.67 Million USD | 54.8% |
| Genus plc | 485 Million USD | 97.514% |
| Pharming Group N.V. | 244.07 Million USD | 95.06% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -217.304% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -215.012% |
| IMV Inc. | 37.93 Million USD | 68.213% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -2.372% |
| MultiCell Technologies, Inc. | 1617.67 USD | -745264.568% |
| ONE Bio Corp. | 27.49 Million USD | 56.148% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 84.425% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 85.461% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -33.347% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 34.482% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -8385.548% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5895.316% |
| Alpha Cognition Inc. | 7.16 Million USD | -68.289% |
| Enzolytics Inc. | 365.26 Million USD | 96.699% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 97.29% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -603.474% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 51.275% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.091% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -25.835% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2760.165% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -222.886% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1670.995% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -344.658% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -106.372% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -508.565% |
| Adynxx, Inc. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -1017.226% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -17915.418% |
| EV Biologics, Inc. | 2.11 Million USD | -470.078% |
| Q BioMed Inc. | 8.13 Million USD | -48.256% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 76.012% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 89.844% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | 24.189% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -109.849% |
| HST Global, Inc. | 593.59 Thousand USD | -1931.281% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -43852.681% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -857.561% |
| Halberd Corporation | 728.71 Thousand USD | -1554.621% |
| Resverlogix Corp. | 67.39 Million USD | 82.109% |
| Cell Source, Inc. | 15.8 Million USD | 23.719% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1.297% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -201.911% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4952.31% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -53.39% |
| Kadimastem Ltd | 3.5 Million USD | -244.023% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -487.724% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2494.699% |
| LadRx Corporation | 2.2 Million USD | -447.938% |
| Regen BioPharma, Inc. | 5.45 Million USD | -120.931% |
| Affymax, Inc. | 8.87 Million USD | -35.921% |
| Itoco Inc. | 1.65 Million USD | -629.367% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -99.331% |
| Mobile Lads Corp. | 1.31 Million USD | -817.972% |
| International Stem Cell Corporation | 5.27 Million USD | -128.492% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 3.24 Million USD | -271.058% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -28746.477% |
| Qrons Inc. | 1.48 Million USD | -709.93% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -9.165% |
| SYBLEU INC | 681.41 Thousand USD | -1669.491% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1390.805% |
| Rebus Holdings, Inc. | 5.24 Million USD | -130.018% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -97.603% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1826.712% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -161.148% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 70.588% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 45.845% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -495.32% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -120.108% |
| Neutra Corp. | 973.52 Thousand USD | -1138.539% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 58.444% |
| PureTech Health plc | 125.58 Million USD | 90.399% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -220.925% |
| IXICO plc | 1.9 Million USD | -534.51% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 41.266% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 88.33% |
| CSL Limited | 18.62 Billion USD | 99.935% |
| Cellectis S.A. | 249.36 Million USD | 95.165% |